麗珠醫藥(01513.HK)2020年歸母淨利17.15億元 同比增長31.63%
格隆匯 3 月 22日丨麗珠醫藥(01513.HK)公吿，2020年，集團實現營業收入人民幣105.2億元，同比增長12.10%；實現歸屬於公司股東的淨利潤人民幣17.15億元，同比增長31.63%；若剔除非經常性損益項目收益，公司2020年主營業務實現的歸屬於公司股東的淨利潤為人民幣14.3億元，同比增長20.14%。基本每股收益1.83元。擬向公司全體股東每10股派發現金股利人民幣12.50元(含税)。
2020年，集團各業務板塊重點產品持續發力，化學制劑主要產品注射用艾普拉唑鈉銷售同比快速大幅增長，注射用醋酸亮丙瑞林微球、鹽酸哌羅匹隆片、馬來酸氟伏沙明片的銷售同比實現了持續較大幅度的提升；另外，中藥製劑主要產品抗病毒顆粒因疫情影響，銷售同比上年大幅增長；加新型冠狀病毒抗體檢測試劑產品實現新增銷售，得以讓公司整體業績在新冠疫情影響下實現穩步增長。
2020年底，兩款新冠檢測產品又獲歐盟CE認證，進一步擴大了新冠病毒檢測試劑的供應，同時也讓集團產品能夠更好地滿足全球疫情防控的需要。
當下，集團已經駛入創新驅動發展的全新階段。創新藥艾普拉唑系列產品、以及高壁壘複雜製劑注射用醋酸亮丙瑞林微球持續高增長，對集團營收及利潤貢獻佔比進一步提升，雙輪驅動，成為集團高速發展的強大引擎。
此外，集團研發管線中來自生物藥、微球等平台的品種和業務也為公司的經營發展注入了新的活力。公司生物藥研發管線涉及腫瘤、生殖、免疫疾病等領域的新型抗體、多特異性抗體、重組蛋白類藥物，同時公司也在不斷推進ADC技術平台和新型CAR-T技術等平台建設，並與國內大分子生物藥研發公司、國際一流科學家、美國新鋭細胞治療公司、中國科學院生物物理研究所等密切合作，多個在研產品正在加快臨牀推進速度。
另外，對於高壁壘複雜製劑平台，公司將繼續擴大國內微球領域創新研發的領先優勢，進行了一系列豐富的在研品種佈局，其中不乏高銷售潛力的重磅品種，集團還匯聚了該領域頂尖人才，並獲得國家重大新藥創制專項獎勵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
